1. Academic Validation
  2. Improved P2 phenylglycine-based hepatitis C virus NS3 protease inhibitors with alkenylic prime-side substituents

Improved P2 phenylglycine-based hepatitis C virus NS3 protease inhibitors with alkenylic prime-side substituents

  • Bioorg Med Chem. 2010 Jul 15;18(14):5413-24. doi: 10.1016/j.bmc.2010.05.027.
Anna Lampa 1 Angelica E Ehrenberg Sofia S Gustafsson Aparna Vema Eva Kerblom Gunnar Lindeberg Anders Karlén U Helena Danielson Anja Sandström
Affiliations

Affiliation

  • 1 Department of Medicinal Chemistry, Organic Pharmaceutical Chemistry, Uppsala University, BMC, Box 574, SE-751 23 Uppsala, Sweden.
Abstract

Phenylglycine has proved to be a useful P2 residue in HCV NS3 Protease Inhibitors. A novel pi-pi-interaction between the phenylglycine and the catalytic H57 residue of the protease is postulated. We hypothesized that the introduction of a vinyl on the phenylglycine might strengthen this pi-pi-interaction. Thus, herein is presented the synthesis and inhibitory potency of a series of acyclic vinylated phenylglycine-based HCV NS3 Protease Inhibitors. Surprisingly, inhibitors based on both D- and L-phenylglycine were found to be effective inhibitors, with a slight preference for the d-epimers. Furthermore, prime-side alkenylic extension of the C-terminal acylsulfonamide group gave significantly improved inhibitors with potencies in the nanomolar range (approximately 35 nM), potencies which were retained on mutant variants of the protease.

Figures